P
Pierre Fabre
Pioneering allogeneic cell therapies for oncology and rare diseases with a focus on unmet patient needs
About Pierre Fabre
Pierre Fabre Pharmaceuticals, a US subsidiary of Pierre Fabre Laboratories, is dedicated to advancing the field of oncology and rare diseases through the development of allogeneic cell therapies. The company targets patients with high unmet medical needs, aiming to deliver breakthrough treatments that address these critical areas. Operating within the pharmaceutical and biotech industries, Pierre Fabre Pharmaceuticals leverages its extensive expertise in clinical manufacturing and distribution to support the commercialization of its innovative therapies. The business model focuses on partnering with biotechs to bring these therapies to market, generating revenue through successful product launches and strategic collaborations. With a seasoned leadership team, the company is well-positioned to establish a strong presence in the US market, emphasizing long-term success and patient care.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1951
- Headquarters
- Toulouse, France
- Employees
- 9,750
- Open positions
- 259
- Dealroom signal
- 75.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Horizon Europe, observatoire healthtech
- Business model
- Manufacturing
- Client focus
- b2b, b2c
- Investment activity
- 5 companies, latest Sep 2023
- Capital deployed
- $36M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jan 2022 | $14M | $55M | Yuansheng Venture Capital · Shanna Capital · Shunwei Capital · Taiyu Ankang | ↗ |
Growth signals
Latest recorded traffic for Pierre Fabre is 100K monthly website visits, up 28.2% over the last three months. Pierre Fabre's team grew 7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vertical BioBasel, Switzerland
→
MiYéAntibes, FranceNatural skincare and supplements for female hormonal balance
→
TOLREMO therapeuticsBasel, SwitzerlandFocused on the discovery and development of small molecules to prevent resistance in cancer therapy
$125Mvaluation
Même CosmeticsParis, FrancePremium skincare and hair care products made with natural ingredients in France, created in collaboration with clients, with over 1358 reviews in the past 12 months, featuring positive feedback on product quality, ease of use, and
$4Mvaluation
RibonexusVillejuif, FranceA biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
- YCYuansheng Venture Capital
- SCShanna Capital
Shunwei Capital- TATaiyu Ankang
- BXBeijing Xinghang
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pierre Fabre on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pierre Fabre’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.